Centene Corp (NYSE:CNC) Director Orlando Ayala sold 9,878 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $65.36, for a total value of $645,626.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Orlando Ayala also recently made the following trade(s):
- On Monday, June 22nd, Orlando Ayala sold 30,000 shares of Centene stock. The shares were sold at an average price of $63.87, for a total value of $1,916,100.00.
CNC stock opened at $65.25 on Friday. The company has a current ratio of 1.22, a quick ratio of 1.14 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $37.79 billion, a PE ratio of 22.89, a PEG ratio of 0.97 and a beta of 0.73. Centene Corp has a 1-year low of $41.62 and a 1-year high of $74.70. The business’s 50 day simple moving average is $64.50 and its 200 day simple moving average is $63.43.
Several equities research analysts have commented on the company. Morgan Stanley boosted their target price on Centene from $85.00 to $89.00 and gave the company an “overweight” rating in a research note on Monday, April 13th. Credit Suisse Group reaffirmed a “hold” rating and set a $72.50 price target on shares of Centene in a research report on Wednesday, April 29th. Jefferies Financial Group lowered their price target on Centene from $85.00 to $83.00 and set a “buy” rating on the stock in a research report on Wednesday. Oppenheimer started coverage on Centene in a research report on Friday, June 12th. They set a “buy” rating and a $90.00 price target on the stock. Finally, TheStreet raised Centene from a “c+” rating to a “b” rating in a research report on Wednesday, April 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $82.92.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in Centene by 41.8% during the first quarter. BlackRock Inc. now owns 44,354,139 shares of the company’s stock worth $2,635,080,000 after purchasing an additional 13,078,726 shares during the period. State Street Corp boosted its holdings in Centene by 45.2% in the first quarter. State Street Corp now owns 24,458,142 shares of the company’s stock worth $1,453,058,000 after acquiring an additional 7,617,774 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Centene by 45.3% in the first quarter. Wellington Management Group LLP now owns 18,929,221 shares of the company’s stock worth $1,124,586,000 after acquiring an additional 5,898,593 shares in the last quarter. Viking Global Investors LP boosted its holdings in Centene by 48.8% in the first quarter. Viking Global Investors LP now owns 16,230,552 shares of the company’s stock worth $964,257,000 after acquiring an additional 5,323,440 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Centene by 330.8% in the first quarter. Janus Henderson Group PLC now owns 6,532,036 shares of the company’s stock worth $388,066,000 after acquiring an additional 5,015,840 shares in the last quarter. 93.58% of the stock is owned by institutional investors.
Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. The company's Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which covers dually eligible individuals, as well as aged, blind, or disabled programs.
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.